3rd Quarter - Amendment

ALLERGAN USA, INC. for ALLERGAN USA, INC.

Firm
Client
Income
—
Expenses
$850,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report Oct 19, 2016 $820,000 Replaced
3rd Quarter - Amendment (this page) May 19, 2017 $850,000 Yes

What was lobbied

8 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation. Promoting the social contract with patients to ensure they have affordable access to critical innovative medicines.

LobbyistCovered position, as disclosed
BRENT J FISK —
ROBERT W. LIVELY —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS)

Copyright/Patent/Trademark CPT

Patent Reform Proposals. Patent Settlement Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.

LobbyistCovered position, as disclosed
BRENT J FISK —
ROBERT W. LIVELY —

Contacted: Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA)

Pharmacy PHA

Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace

LobbyistCovered position, as disclosed
BRENT J FISK —
ROBERT W. LIVELY —

Contacted: SENATE; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.

Foreign entity interest: Allergan plc, as the indirect parent of Allergan USA, Inc., has an interest to the extent the tax code affects foreign operations.

LobbyistCovered position, as disclosed
BRENT J FISK —
ROBERT W. LIVELY —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO); Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016. Supporting investment in the innovation of safe, quality, accessible, and affordable biopharma products.

LobbyistCovered position, as disclosed
BRENT J FISK —
ROBERT W. LIVELY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Patent & Trademark Office (PTO)

Bills named: S. 2680 (114th), H.R. 2646 (114th)

Medicare/Medicaid MMM

Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases. Protecting patients from demonstrations, regulations, and rules that would limit access to life-saving medicines.

LobbyistCovered position, as disclosed
BRENT J FISK —
ROBERT W. LIVELY —

Contacted: Patent & Trademark Office (PTO); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA)

Medical/Disease Research/Clinical Labs MED

Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.

LobbyistCovered position, as disclosed
BRENT J FISK —
ROBERT W. LIVELY —

Contacted: Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; Patent & Trademark Office (PTO)

Budget/Appropriations BUD

Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations. Continuing oversight of the integrity of the pharmaceutical supply chain.

LobbyistCovered position, as disclosed
BRENT J FISK —
ROBERT W. LIVELY —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Patent & Trademark Office (PTO)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.